How Sensory Nerves Drive Inflammation Through Peptide Release: A Century of Discovery

What the researchers found

This historical review traces more than a century of research on how sensory nerves drive inflammation — a process called neurogenic inflammation. Sensory nerves don't just detect pain; they actively release peptides that dilate blood vessels and recruit immune cells.

The key neuropeptides identified as drivers of neurogenic inflammation include substance P (which causes vasodilation and plasma leakage) and CGRP (calcitonin gene-related peptide, a potent vasodilator). Sensory nerves also release anti-inflammatory peptides like endogenous opioids and somatostatin, showing the system has built-in brakes. The discovery of TRP channels (particularly TRPV1) revealed how these nerves sense environmental stimuli like heat, chemicals, and injury — providing the molecular mechanism linking tissue damage to neuropeptide release and inflammation.

Why it matters

Neurogenic inflammation sits at the crossroads of pain and immune function, and the neuropeptides involved (substance P, CGRP, somatostatin) are now therapeutic targets. CGRP-blocking drugs have already revolutionized migraine treatment, and substance P antagonists are used for chemotherapy-induced nausea. Understanding this century-old field helps explain why peptide-based therapies targeting sensory nerve pathways are among the most promising approaches to inflammatory disease.

How the study worked

Narrative historical review covering research from the initial discovery of sensory nerve function through modern molecular characterization of neuropeptides and TRP channels. Synthesizes findings across vascular biology, pain research, and immunology.

Who was studied

Review article (no study population)

What this study cannot tell us

As a narrative review, this paper summarizes and interprets existing literature rather than presenting new data. The authors note that despite over a century of research, the precise role of sensory nerves in vascular inflammation versus pain processing remains unclear, highlighting gaps in the field.

How to read the evidence

This is a narrative review article that synthesizes existing research rather than presenting new experimental data. Reviews are valuable for context and identifying trends but don't generate primary evidence.

When this study was published

Published in 2018. The historical perspective and fundamental mechanisms described remain relevant, though the therapeutic landscape (especially CGRP-targeting drugs) has advanced significantly since publication.

The bigger picture

This review contextualizes why neuropeptides are now hot therapeutic targets. CGRP-blocking antibodies (like erenumab) transformed migraine treatment, and substance P antagonists (like aprepitant) prevent chemotherapy nausea. Understanding the full landscape of neurogenic inflammation helps explain the rationale behind current and emerging peptide therapies targeting pain, vascular disease, and chronic inflammatory conditions.

Questions still open

• Can we selectively enhance the anti-inflammatory neuropeptides (somatostatin, opioids) released by sensory nerves while dampening pro-inflammatory ones?
• How do TRP channel-targeted therapies compare to directly blocking neuropeptides like CGRP for treating inflammatory conditions?
• What role does neurogenic inflammation play in chronic conditions like rheumatoid arthritis or inflammatory bowel disease?

Common questions

Read the original research

A historical perspective on the role of sensory nerves in neurogenic inflammation.

Seminars in immunopathology, 40(3), 229-236

Citation

Sousa-Valente, João; Brain, Susan D. (2018). A historical perspective on the role of sensory nerves in neurogenic inflammation.. Seminars in immunopathology, 40(3), 229-236. https://doi.org/10.1007/s00281-018-0673-1